Last reviewed · How we verify

Genrix (Shanghai) Biopharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief

Genrix (Shanghai) Biopharmaceutical Co., Ltd. pipeline: 0 marketed, 0 filed, 6 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 6 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
GR1501 high dose GR1501 high dose phase 3 PD-1 inhibitor PD-1 Oncology
GR2001 GR2001 phase 3
GR1801 GR1801 phase 3
GR1802 injection GR1802 injection phase 3 PD-1 inhibitor PD-1 Oncology
GR1501 low dose GR1501 low dose phase 3
GR1803 GR1803 phase 3 Bispecific antibody Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Amgen · 3 shared drug classes
  2. Sanofi · 3 shared drug classes
  3. Pfizer · 3 shared drug classes
  4. Janssen Research & Development, LLC · 2 shared drug classes
  5. GlaxoSmithKline · 2 shared drug classes
  6. Hoffmann-La Roche · 2 shared drug classes
  7. Bristol-Myers Squibb · 2 shared drug classes
  8. Assistance Publique - Hôpitaux de Paris · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Genrix (Shanghai) Biopharmaceutical Co., Ltd.:

Cite this brief

Drug Landscape (2026). Genrix (Shanghai) Biopharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/genrix-shanghai-biopharmaceutical-co-ltd. Accessed 2026-05-16.

Related